Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Phase II, Dose Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of oral Litoxetine 10mg, 20mg and 40mg Twice Daily (BID) versus placebo in women with Mixed Urinary Incontinence

Next Previous
X
Search
Trial Profile

A Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Phase II, Dose Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of oral Litoxetine 10mg, 20mg and 40mg Twice Daily (BID) versus placebo in women with Mixed Urinary Incontinence

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Litoxetine (Primary)
  • Indications Mixed incontinence; Urinary incontinence
  • Focus Proof of concept; Therapeutic Use
  • Sponsors IXALTIS

    • Most Recent Events

    • 20 Apr 2019 This trial was completed in Poland, according to European Clinical Trials Database.
    • 31 Aug 2018 Results presented at the 48th Annual Meeting of the International Continence Society
    • 25 Jul 2018 This trial was completed in France, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top